Head-to-head · Cost-Efficiency Index
CoreAge Rx vs NuuVim
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
CoreAge Rx
Anyone optimizing for real value — a transparent flat price you can model for a full year, nationwide, without a bait-and-switch.
Visit CoreAge RxNuuVim
Cost-first shoppers who want low-cost compounded GLP-1s (injection or oral), flat all-dose pricing.
Visit NuuVimThe verdict
CoreAge Rx takes it, leading the Cost-Efficiency Index 94 to 71. Best value on the board: both molecules at one flat, all-50 price with no teaser step-ups — the lowest true cost of ownership, not the lowest teaser. NuuVim still earns a C — Cost-first shoppers who want low-cost compounded GLP-1s (injection or oral), flat all-dose pricing.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | CoreAge Rx | NuuVim |
|---|---|---|
| Cost-Efficiency Index | 94/100 | 71/100 |
| Semaglutide / mo | $149/mo | $79/mo (all doses, compounded) |
| Tirzepatide / mo | $349/mo | $133/mo (all doses, compounded) |
| Semaglutide / yr (modeled) | $1,788 | $948 |
| Tirzepatide / yr (modeled) | $4,188 | $1,596 |
| Coverage | All 50 states | Coverage not published |
| Oral / sublingual | No | Yes |
| Brand-name access | Compounded only | Yes |
| Rank on the board | #1 | #91 |
CoreAge Rx
94/100Where the value is
- Flat all-in monthly price — no intro rate that silently triples after month one, so the modeled annual cost is the real cost
- Both compounded semaglutide and tirzepatide on one account at published prices
- Available in all 50 states — no coverage gamble
The tradeoffs
- Not the rock-bottom sticker price — cheaper teaser tiers exist (Direct GLP lists $65, Ondra $93 on semaglutide)
- No FDA-approved brand-name option (compounded only)
NuuVim
71/100Where the value is
- Low compounded entry pricing — semaglutide from $79/mo, tirzepatide from $133/mo, flat all-dose pricing
- Both injectable and oral compounded options for semaglutide and tirzepatide (oral access is uncommon)
- LegitScript Certified and HIPAA-compliant
The tradeoffs
- No founder, CEO, medical director, or pharmacist-in-charge named
- Refund and cancellation policy not surfaced on the site
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.